Patients ( N = @ ) with mixed dyslipidemia on a standard statin dose ( @-@mg simvastatin or @-@mg atorvastatin or @-@mg rosuvastatin ) who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin ( @mg/day ) or to add-on-statin extended release nicotinic acid ( ER-NA ) / laropiprant ( LRPT ) ( @/@mg/day for the first @weeks followed by @/@mg/day for the next @weeks ) or to add-on-statin micronized fenofibrate ( @mg/day ) for a total of @months .